◎ Sugi Atlas

Atlas / Drug / Minocycline

Minocycline

drug
On this page

Also known as MinociclinaSID124894250SID144207192Minocin

Summary

Minocycline (CHEMBL1434) is an approved small-molecule antibacterial drug (ATC A01AB23); indicated across 73 conditions including acne and bacterial infectious disease.

At a glance

  • Status: Approved (max clinical phase 4)
  • Modality: Small molecule
  • ATC class: A01AB23 (+2 more)
  • Indications: 73 conditions
  • Clinical trials: 177
  • Chemistry: 457.5 Da · C23H27N3O7

Identifiers

Drug identity and classification

FieldValue
ChEMBL IDCHEMBL1434
NameMinocycline
TypeSmall molecule
Max phase4
FDA approvedno
PubChem CID54675783
ChEBICHEBI:50694
ATCA01AB23, D10AF07, J01AA08
Molecular formulaC23H27N3O7
Molecular weight457.5
InChIKeyFFTVPQUHLQBXQZ-KVUCHLLUSA-N

SMILES: CN(C)[C@H]1[C@@H]2C[C@@H]3CC4=C(C=CC(=C4C(=C3C(=O)[C@@]2(C(=C(C1=O)C(=O)N)O)O)O)O)N(C)C

IUPAC name: (4S,4aS,5aR,12aR)-4,7-bis(dimethylamino)-1,10,11,12a-tetrahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4H-tetracene-2-carboxamide

ChEBI definition: A tetracycline analogue having a dimethylamino group at position 7 and lacking the methyl and hydroxy groups at position 5.

Pharmacological roles (ChEBI): antibacterial drug, geroprotector.

Other ChEBI roles (chemical / environmental): Escherichia coli metabolite.

Also known as: Minociclina, Minocycline, minocycline, MINOCYCLINE, SID124894250, SID144207192, Minocin

Parent form; salt/anhydrous children: CHEMBL1200881

Patent coverage: 16,513 distinct patent families (62,058 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 62,054 (100%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 4 (assay-derived). Sample: Prostaglandin G/H synthase 1, Albumin, Multidrug transporter MdfA, Bile salt export pump.

Bioactivity

ChEMBL activities: 2 potent at pChembl ≥ 5 of 4 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

TargetpChemblTypeValueUnitActivity ID
PTGS15.6AC502503nMCHEMBL_ACT_25205936
P0AEY85.58IC502600nMCHEMBL_ACT_85487

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

73 indications (3 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

IndicationTrial phaseMONDOEFO
acne4MONDO:0011438EFO:0003894
bacterial infectious disease4MONDO:0005113EFO:0000771
rosacea3MONDO:0006604EFO:1000760
hypertensive disorder3MONDO:0005044EFO:0000537
periodontitis3MONDO:0005076EFO:0000649
psychotic disorder3MONDO:0005485EFO:0005407
heroin dependence3MONDO:0005367EFO:0004240
rheumatoid arthritis3MONDO:0008383EFO:0000685
idiopathic pulmonary fibrosis3MONDO:0800504EFO:0000768
schizoaffective disorder3MONDO:0005487EFO:0005411
spinal cord injury3MONDO:0043797EFO:1001919
lichen planus, oral3MONDO:0043923EFO:0008517
pneumothorax3MONDO:0002076HP:0002107
depressive disorder3MONDO:0002050MONDO:0002050
amyotrophic lateral sclerosis3MONDO:0004976MONDO:0004976
multiple sclerosis3MONDO:0005301MONDO:0005301
bipolar disorder3MONDO:0004985MONDO:0004985
drug dependence3MONDO:0005303EFO:0003890
obsessive-compulsive disorder2MONDO:0008114EFO:0004242
HIV infectious disease2MONDO:0005109EFO:0000764
non-small cell lung carcinoma2MONDO:0005233EFO:0003060
plasma cell myeloma2MONDO:0009693EFO:0001378
stroke disorder2MONDO:0005098EFO:0000712
exocrine pancreatic carcinoma2MONDO:0005192EFO:0002618
relapsing-remitting multiple sclerosis2MONDO:0005314EFO:0003929
impetigo2MONDO:0004592EFO:1000714
age-related macular degeneration2MONDO:0005150EFO:0001365
internal carotid artery stenosis2MONDO:0005189EFO:0002615
retinal detachment2MONDO:0008375EFO:0005773
head and neck cancer2MONDO:0005627EFO:0006859
oropharynx cancer2MONDO:0004608EFO:1001931
atrial fibrillation2MONDO:0004981EFO:0000275
neuralgia2MONDO:0021667EFO:0009430
major depressive disorder2MONDO:0002009MONDO:0002009
lung neoplasm2MONDO:0021117MONDO:0008903
asthma2MONDO:0004979MONDO:0004979
Parkinson disease2MONDO:0005180MONDO:0005180
Angelman syndrome2MONDO:0007113MONDO:0007113
Huntington disease2MONDO:0007739MONDO:0007739
cystic fibrosis2MONDO:0009061MONDO:0009061
fragile X syndrome2MONDO:0010383MONDO:0010383
Mycobacterium avium complex disease2MONDO:0005866EFO:0007386
inflammatory bowel disease2MONDO:0005265EFO:0003767
colorectal neoplasm2MONDO:0005335MONDO:0005575
autoimmune disorder of the nervous system2MONDO:0002977MONDO:0020640
intracerebral hemorrhage1MONDO:0013792EFO:0005669
skin disorder1MONDO:0005093EFO:0000701
sclerosing cholangitis1MONDO:0018646EFO:0004268
glioblastoma1MONDO:0018177EFO:0000519
pneumonia1MONDO:0005249EFO:0003106
autism spectrum disorder1MONDO:0005258EFO:0003756
retinal vein occlusion1MONDO:0006951EFO:1001157
periapical periodontitis1MONDO:0004508EFO:1001391
autism1MONDO:0005260EFO:0003758
brain injury1MONDO:0043510MONDO:0043510
fibromyalgia1MONDO:0005546EFO:0005687
glioma1MONDO:0021042MONDO:0100342
alcohol abuse1MONDO:0002046MONDO:0007079
retinitis pigmentosa1MONDO:0019200MONDO:0019200
cerebral amyloid angiopathy1MONDO:0005620EFO:0006790
paraganglioma1MONDO:0000448EFO:1000453
osteomyelitis0MONDO:0005246EFO:0003102

11 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 177.

Phase distribution

PhaseTrials
PHASE243
PHASE437
PHASE323
PHASE1/PHASE222
PHASE121
Not specified21
PHASE2/PHASE38
EARLY_PHASE12

Top trials by phase / activity

NCTPhaseStatusTitle
NCT05487417PHASE4RECRUITINGEffects of Minocycline on Patients With Ischemic Stroke Undergoing Intravenous Thrombectomy
NCT05512910PHASE4ACTIVE_NOT_RECRUITINGMinocycline for Acute Ischemic Stroke Undergoing Endovascular Treatment Due to Basilar Artery Occlusion (MIST-B)
NCT06523764PHASE4ACTIVE_NOT_RECRUITINGEfficacy and Safety of Tegoprazan and Minocycline Dual Therapy for Helicobacter Pylori Initial Treatment
NCT06561698PHASE4RECRUITINGHigh-dose Dual Therapy and Minocycline-cotaining Quadruple Therapy for Helicobacter Pylori Infection
NCT06699966PHASE4NOT_YET_RECRUITINGStony Brook Medicine Anti-Inflammatory Trial
NCT07068607PHASE4RECRUITINGEfficacy Comparison of Vonoprazan Combined With Different Antibiotics in Dual Therapy for Helicobacter Pylori Eradication: A Prospective, Randomized Controlled Clinical Trial
NCT00145106PHASE4COMPLETEDComparison of Tazarotene and Minocycline Therapies for Maintenance of Facial Acne Vulgaris
NCT00240513PHASE4TERMINATEDStudy Comparing Acne in Patients Taking Oral Minocycline to Patients Taking Minocycline Plus Topical Tretinoin
NCT00409747PHASE4COMPLETEDMinocycline to Treat Childhood Regressive Autism
NCT00668746PHASE4COMPLETEDLong-term Safety of Minocycline in Patients With Gum Disease
NCT00930020PHASE4TERMINATEDNeuroprotection With Minocycline Therapy for Acute Stroke Recovery Trial
NCT01133080PHASE4UNKNOWNMinocycline as an Adjunctive Therapy for Schizophrenia: a Randomized Controlled Study
NCT01206348PHASE4COMPLETEDCombination Treatment for Moderate to Severe Acne
NCT01493622PHASE4COMPLETEDThe Study of Minocycline for Negative and Cognitive Symptoms in Schizophrenia
NCT01514422PHASE4COMPLETEDMinocycline for Bipolar Depression
NCT01809158PHASE4COMPLETEDMinocycline for Schizophrenia
NCT01869907PHASE4COMPLETEDEffect of Minocycline on Pain Caused by Nerve Damage
NCT02124811PHASE4COMPLETEDMinocycline Augmentation to Clozapine
NCT02263872PHASE4COMPLETEDMinocycline as an Adjunct for the Treatment of Depressive Symptoms: Pilot Randomized Controlled Trial
NCT02355977PHASE4COMPLETEDThe Response of Pathogens to the Respective or Combined Treatment of SRP and Local Minocycline in Chronic Periodontitis
NCT02695446PHASE4COMPLETEDAdministration of Oral Extended Release Minocycline for Assessment of Skin and Plasma Concentrations of Minocycline
NCT02719392PHASE4SUSPENDEDA Pilot Study Investigating the Efficacy of Minocycline and N-Acetyl Cysteine for Bipolar Depression
NCT02968602PHASE4COMPLETEDMinocycline and Tobacco Craving in Smokers With Schizophrenia
NCT03340350PHASE4COMPLETEDMinocycline for Treatment of Posttraumatic Stress Disorder in Veterans
NCT03369951PHASE4COMPLETEDMinocycline Pharmacokinetics (ACUMIN)
NCT03762915PHASE4COMPLETEDScaling and Root Planing (SRP) With and Without Minocycline HCl Microspheres, 1 mg
NCT04020588PHASE4UNKNOWNAnti-inflammatories and Adolescent Schizophrenia
NCT04531059PHASE4COMPLETEDRescue Therapy for Helicobacter Pylori Eradication Treatment
NCT04558502PHASE4UNKNOWNEffectiveness of Minocycline-Containing Bismuth Quadruple Therapy for Helicobacter Pylori Eradication
NCT05014906PHASE4COMPLETEDEfficacy of Oral Minocycline (Solodyn) and Oral Minocycline (Solodyn) Plus Azelaic Acid (Finacea) for Acne Rosacea
NCT05530252PHASE4COMPLETEDEffects of AMP Application After Non-surgical Periodontal Therapy on Treatment of Periodontitis
NCT05575427PHASE4UNKNOWNEfficacy of Combination Therapy With Minocycline for Treatment of Stenotrophomonas Maltophilia Infections
NCT05586815PHASE4UNKNOWNEfficacy of Colistin Monotherapy Versus Colistin Plus Minocycline for Carbapenem-Resistant A. Baumannii Infection
NCT06044090PHASE4COMPLETEDBrain and Stress Study
NCT06307288PHASE4UNKNOWNEfficacy and Safety of Tranilast Combined With Minocycline in the Treatment of Rosacea
NCT06561711PHASE4COMPLETEDOptimization of Minocycline for Helicobacter Pylori Rescue Treatment
NCT06603688PHASE4UNKNOWNStudy on the Efficacy and Safety of Berberine, Minocycline, Esomeprazole, and Colloidal Bismuth Quadruple Therapy in the Initial Treatment of Helicobacter Pylori.
NCT03414502PHASE3RECRUITINGTreatment of Rheumatoid Arthritis With DMARDs: Predictors of Response
NCT07082855PHASE3NOT_YET_RECRUITINGA Multicenter, Randomized, Double-Blind, Controlled Clinical Study of Minocycline for the Treatment of Retinitis Pigmentosa
NCT07237048PHASE2/PHASE3RECRUITINGMinocycline in Stroke Study at Maimonides

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).

About this page

Generated deterministically by Sugi Atlas from primary biomedical databases via BioBTree. Every record on this page traces to a primary source.

Generated
Atlas version
v1.1.2
BioBTree
v2.0.2

Sources 17

This page pulls from 17 datasets indexed by BioBTree:

chebichembl_activitychembl_moleculechembl_targetcivic_evidenceclinical_trialsefogtopdb_interactiongtopdb_ligandhgncmeshmondopatent_compoundpharmgkbpharmgkb_guidelinepubchemuniprot